W. Joost Lesterhuis

Dr W. Joost Lesterhuis has a background as a dual-trained medical oncologist and basic researcher in tumour immunology and cancer biology. He received clinical training as a medical oncologist at the Radboud University Nijmegen Medical Centre in the Netherlands, while combining it with a PhD in tumour immunology. Since 2018, Joost heads the Sarcoma Translational Research at Telethon Kids Institute as an honorary research fellow, while also continuing research programme at UWA. Joost’s research combines several fields of science; cancer biology, immunology, drug discovery, systems biology and translational oncology. The central theme of research at the Joost’s sarcoma group is the development of local immunotherapy treatment which is used to prevent sarcoma relapse at the site of surgery, and they are applying systems biology and drug discovery approaches to map the wound healing response in sarcoma following surgery. In parallel to projects of Sarcoma, Joost also directs research on Immune Checkpoint Blockade therapies.

Lab Information

Sarcoma Lab at Telethon Kids Institute of UWA

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

Sarcoma 0 Paediatric Cancer 0 Immune Checkpoint Blockade therapies 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (1)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Rwandamuriye FX, Weston BJ, Johns TG, Lesterhuis WJ, Zemek RM. A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies. J Vis Exp. 2020;(161):10.3791/60882. Published 2020 Jul 28. doi:10.3791/60882

  2. Zemek RM, Fear VS, Forbes C, et al. Bilateral murine tumor models for characterizing the response to immune checkpoint blockade. Nat Protoc. 2020;15(5):1628-1648. doi:10.1038/s41596-020-0299-3

  3. Zemek RM, Chin WL, Nowak AK, Millward MJ, Lake RA, Lesterhuis WJ. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Front Immunol. 2020;11:223. Published 2020 Feb 18. doi:10.3389/fimmu.2020.00223

  4. Boudewijns S, Bloemendal M, de Haas N, et al. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunol Immunother. 2020;69(3):477-488. doi:10.1007/s00262-019-02466-x

  5. Aston WJ, Hope DE, Cook AM, et al. Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. Oncoimmunology. 2019;8(11):e1641390. Published 2019 Jul 13. doi:10.1080/2162402X.2019.1641390


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2026 MolecularCloud